IMMVF News Alert Immuno Vaccine Inc (IMMVF) 0.7760 10/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Immuno Vaccine Inc (IMMVF) 0.7760 $IMMVF

Immunovaccine Announces Plans for Phase II Clinical Trial of DPX-Survivac in Patients with Recurrent Lymphoma
Marketwire - Wed Oct 01, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today provided a clinical development program update for DPX-Survivac, the Company's lead cancer vaccine candidate. Following the presentation of positive Phase I/II clinical trial data at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting earlier this year, the Company plans to advance DPX-Survivac into a Phase II clinical study in diffuse large B cell lymphoma (DLBCL) later this year. The trial will evaluate DPX-Survivac in combination with oral cyclophosphamide, an immune modulating agent, in patients with recurrent DLBCL. This combination therapy trial design fits with Immunovaccine's clinical development strategy of maximizing therapeutic impact through concurrent treatment with various classes of promising immunotherapies.

Immunovaccine Adds Broad Business Operations and Capital Raising Expertise to Board of Directors with New Appointments
Marketwire - Fri Sep 26, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company" (TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, has elected Wade K. Dawe and Alfred A. Smithers to its board of directors. The appointments are effective immediately.

Global Ebola and Marburg Infections Therapeutics Pipeline Report 2014 - 10 Companies & 12 Drug Profiles
M2 - Tue Sep 09, 9:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjrkc2/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola and Marburg Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Crucell N.V. - NanoViricides, Inc. - AlphaVax, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Profectus BioSciences, Inc. - Mapp Biopharmaceutical, Inc. Drug Profiles - Vaccine for Multivalent Filovirus - Ebola Vaccine Marburg Vaccine - Vaccine For Filovirus - Ebola/Marburg Program - Ebola And Marburg Vaccine - Monoclonal Antibody for Marburg Virus - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - MVA-BN-Filoviruses Vaccine - rVSV-Vectored Vaccines - Subunit Vaccine for Multifiloviruses - Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Monoclonal Antibodies for Ebola and Marburg Infections For more information visit http://www.researchandmarkets.com/research/gj...nd_marburg

IIROC Trade Resumption - Immunovaccine Inc.
Newsfile Corp - Tue Aug 26, 1:20PM CDT
Trading resumes in:

IIROC Trade Halt - Immunovaccine Inc.
Newsfile Corp - Tue Aug 26, 7:08AM CDT
The following issues have been halted by IIROC:

Ebola Vaccine Using Immunovaccine's DepoVax Proves Highly Efficacious in Non-Human Primate Study
Marketwire - Mon Aug 25, 9:31AM CDT
Immunovaccine Inc. ("Immunovaccine" (TSX VENTURE: IMV), a clinical stage vaccine company, today announced positive results for a vaccine formulated in its DepoVax(TM) technology in an Ebola virus challenge study performed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). In a preliminary study using cynomolgus monkeys, which are particularly sensitive to the Ebola virus, all vaccinated subjects survived exposure to a lethal dose of the wild type Zaire strain of the virus. All unvaccinated control animals succumbed to the disease.

Immunovaccine Announces Financial Results for Quarter Ended June 30, 2014
Marketwire - Fri Aug 15, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX VENTURE: IMV), a clinical stage vaccine company, today released its financial and operational results for the quarter ended June 30, 2014.

Immunovaccine to Present at Ninth Annual Immunotherapies and Vaccines Summit (ImVacS) Conference
Marketwire - Tue Aug 12, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX VENTURE: IMV), a clinical stage vaccine company, announced today that Marc Mansour, Ph.D., the Company's chief executive officer, will make a presentation at the Ninth Annual Immunotherapies and Vaccines Summit (ImVacS). In addition to his presentation, Dr. Mansour will also serve as chairperson of the conference's "Clinical Updates of Combination Immunotherapies" session. The conference will take place on August 11-14, 2014 at the Marriott Long Wharf Hotel in Boston, MA.

Immunovaccine and Pfenex Report Positive Results from Single Dose Anthrax Vaccine Studies
Marketwire - Tue Apr 01, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" (TSX VENTURE: IMV) and Pfenex Inc. ("Pfenex" today announced positive results from anthrax challenge studies in rabbits using Pfenex's mutant recombinant Protective Antigen (mrPA) formulated with Immunovaccine's DepoVax(TM) delivery system. The studies showed that animals administered a vaccine containing mrPA formulated in DepoVax were protected against a lethal anthrax challenge at a range of antigen doses.

Immunovaccine Announces 2013 Year-End Results
Marketwire - Mon Mar 17, 7:06AM CDT
Immunovaccine Inc. (TSX VENTURE: IMV), a clinical stage vaccine company, today announced its financial and operational results for the year ended December 31, 2013.

MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shanghai Import Expo Draws 4,000 Global Companies Again

Updated Category News Views 132

Shanghai spent last week making a rather pointed commercial argument: China wants to be seen buying, not merely selling. The ninth China International Import Expo, or CIIE, brought together more than 4,000 overseas companies and participants from 162 countries, regions and international organizations. That is a serious gathering by any reasonable measure, even if the...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 85

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading
Getac's Linux Certification Matters at the Rugged Edge

Updated Category News Views 73

Field computers rarely get applause, but they can decide whether a critical operation runs cleanly or turns into a very expensive mess. Getac’s November 19 announcement that its UX10, G140, and V120 rugged devices are certified for Red Hat Enterprise Linux is not the sort of headline that sends investors pounding the table. It is, however, the kind of plumbing work that...

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 28

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 0

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 169

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
SciBase Sets Its 2027 AGM Nominating Committee Early

Updated Category News Views 59

Four names on a committee roster rarely make anyone pound the table, and they should not. Still, SciBase Holding has put an important bit of corporate housekeeping in place for its 2027 Annual General Meeting: the nominating committee that will handle shareholder-facing governance work ahead of the May 20 meeting in Stockholm. For a small listed medical-technology...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 87

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 66

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
AI Search Is Squeezing Clicks, Not Killing Content Yet

Updated Category News Views 121

A search result that answers the question before earning a click is a nasty little disruption, and marketers are plainly feeling around for solid ground. Goodfirms surveyed 192 content marketing professionals for its 2026 Content Engagement Metrics report, and the headline is more resilient than the prevailing panic: 66.3% said organic website traffic grew over the prior...

Continue Reading

Top 5 Most Recently Viewed Articles

EQT AB Faces Challenges Following UBS's Rating Cut

Updated Category News Views 124

EQT AB Stock Drops After UBS Downgrade Recently, shares of EQT AB (ST:EQTAB) took a hit as UBS decided to downgrade the stock from "neutral" to "sell." This change in outlook comes amid rising worries over valuation risks and anticipated earnings in the short term. Market Response and Current Trading Situation Following the downgrade, EQT AB saw its trading price dip by...

Continue Reading
AMTD's 'The Last Dance' Sets Record in Hong Kong Film Scene

Updated Category News Views 221

AMTD's Groundbreaking Film Success AMTD Group Inc., alongside its subsidiaries AMTD IDEA Group (NYSE: AMTD; SGX: HKB) and AMTD Digital Inc. (NYSE: HKD), has achieved a remarkable milestone in the film industry with its new release, 'The Last Dance.' This film has not only shattered nine major records in Hong Kong's cinematic landscape but has also surpassed the impressive...

Continue Reading
Community Healthcare Trust Boosts Q4 Dividend Reflecting Growth

Updated Category News Views 441

Community Healthcare Trust Increases Dividend for Fourth Quarter Community Healthcare Trust Incorporated (NYSE: CHCT) has recently made an exciting announcement regarding its upcoming dividend. This decision reflects the company's ongoing commitment to delivering value to its shareholders and demonstrates its robust financial health. Many investors eagerly await the news...

Continue Reading
NielsenIQ and OpenBrand Partner to Enhance Market Insights

Updated Category News Views 1043

NielsenIQ and OpenBrand Forge a Revolutionary Alliance NielsenIQ (NIQ) stands at the forefront of consumer intelligence, and their recent partnership with OpenBrand is set to redefine the landscape of market intelligence in the consumer electronics sector. This collaboration harnesses both companies' strengths to offer advanced solutions designed for retailers,...

Continue Reading
Florida Quantum Initiative Sparks Revolutionary Tech Development

Updated Category News Views 327

Florida Quantum Initiative Launched to Boost Technology Innovation MIAMI — Just recently, leaders from Florida's technology sector proclaimed the launch of Florida Quantum, a groundbreaking initiative designed to accelerate and organize the state's quantum economy. This exciting announcement came during the eMerge Americas' Tech Basel AI Summit Miami, showcasing...

Continue Reading